Adeno-associated virus gene transfer in Morquio A disease - Effect of promoters and sulfatase-modifying factor 1

FEBS Journal

Volumn 277, Issue 17, 2010, Pages 3608-3619

  Alméciga Díaz, Carlos J ^a   Montaño, Adriana M ^b   Tomatsu, Shunji ^b   Barrera, Luis A ^a  

^a PONTIFICIA UNIVERSIDAD JAVERIANA   (Colombia)

^b SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

adeno associated virus derived vector; cytomegalovirus immediate early enhancerpromoter; mucopolysaccharidosis IVA; N acetylgalatosamine 6 sulfate sulfatase; sulfatase modifying factor 1 (SUMF1)

Indexed keywords

COMPLEMENTARY DNA; N ACETYLGALACTOSAMINE 6 SULFATASE; PARVOVIRUS VECTOR; SULFATASE; SULFATASE MODIFYING FACTOR 1; UNCLASSIFIED DRUG; GALNS PROTEIN, HUMAN; N ACETYLGALACTOSAMINE 4 SULFATASE; SUMF1 PROTEIN, HUMAN;

ADENO ASSOCIATED VIRUS; ANIMAL CELL; ARTICLE; CARTILAGE CELL; CELL STRAIN HEK293; CONTROLLED STUDY; CYTOMEGALOVIRUS; DOWN REGULATION; EMBRYO; ENZYME ACTIVITY; EUKARYOTE; FIBROBLAST; GENE TRANSFER; GENETIC TRANSDUCTION; HUMAN; HUMAN CELL; MORQUIO SYNDROME; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROMOTER REGION; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; ANIMAL; CELL LINE; DEPENDOPARVOVIRUS; ENZYMOLOGY; GENE VECTOR; GENETIC TRANSFECTION; GENETICS; METABOLISM;

ADENO-ASSOCIATED VIRUS; CYTOMEGALOVIRUS; EUKARYOTA; MURINAE;

ANIMALS; CELL LINE; CHONDROITINSULFATASES; DEPENDOVIRUS; GENETIC VECTORS; HUMANS; MICE; MUCOPOLYSACCHARIDOSIS IV; PROMOTER REGIONS, GENETIC; SULFATASES; TRANSFECTION;

EID: 77955809447     PISSN: 1742464X     EISSN: 17424658     Source Type: Journal    
DOI: 10.1111/j.1742-4658.2010.07769.x     Document Type: Article

References (85)

1. Neufeld E Muenzer J (2001) The mucopolysaccharidoses. In The Metabolic and Molecular Bases of Inherited Diseases (Scriver C, Beaudet A, Sly W Valle D eds pp. 3421 3452. McGraw-Hill
2. Montaño AM, Tomatsu S, Gottesman G, Smith M Orii T (2007) International Morquio A registry: clinical manifestation and natural course of Morquio A disease. J Inherit Metab Dis 30, 165 174.
3. Ashworth JL, Biswas S, Wraith E Lloyd IC (2006) Mucopolysaccharidoses and the eye. Surv Ophthalmol 51, 1 17.
4. Vellodi A, Young EP, Cooper A, Wraith JE, Winchester B, Meaney C, Ramaswami U Will A (1997) Bone marrow transplantation for mucopolysaccharidosis type I: experience of two British centres. Arch Dis Child 76, 92 99.
5. Tomatsu S, Montaño A, Ohashi A, Oikawa H, Oguma T, Dung V, Nishioka T, Orii T Sly W (2008) Enzyme replacement therapy in a murine model of Morquio A syndrome. Hum Mol Genet 17, 815 824.
6. Beutler E (2006) Lysosomal storage diseases: natural history and ethical and economic aspects. Mol Genet Metab 88, 208 215.
7. Dobbelstein M (2003) Viruses in therapy - royal road or dead end? Virus Res 92, 219 221.
8. Bosch A, Perret E, Desmaris N Heard JM (2000) Long-term and significant correction of brain lesions in adult mucopolysaccharidosis type VII mice using recombinant AAV vectors. Mol Ther 1, 63 70.
9. Herzog R, Yang E, Couto L, Hagstrom J, Elwell D, Fields P, Burton M, Bellinger D, Read M, Brinkhous K et al. (1999) Long-term correction of canine hemophilia B by gene transfer of blood coagulation factor IX mediated by adeno-associated viral vector. Nat Med 5, 56 63.
10. Mah C, Cresawn K, Fraites T, Pacak C, Lewis M, Zolotukhin I Byrne B (2005) Sustained correction of glycogen storage disease type II using adeno-associated virus serotype 1 vectors. Gene Ther 12, 1405 1409.
11. Collas P (1998) Modulation of plasmid DNA methylation and expression in zebrafish embryons. Nucleic Acids Res 26, 4454 4461.
12. Manno CS, Pierce GF, Arruda VR, Glader B, Ragni M, Rasko JJE, Ozelo MC, Hoots K, Blatt P, Konkle B et al. (2006) Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response. Nat Med 12, 342 347.
13. Nakai H, Herzog R, Hagstrom J, Walter J, Kung S, Yang E, Tai S, Iwaki Y, Kurtzman G, Fisher K et al. (1998) Adeno-associated viral vector-mediated gene transfer of human blood coagulation factor IX into mouse liver. Blood 91, 4600 4607.
14. Mingozzi F, Hasbrouck NC, Basner-Tschkarajan E, Edmonson SA, Hui DJ, Sabatino DE, Zhou S, Wright JF, Jiang H, Pierce GF et al. (2007) Modulation of tolerance to the transgene product in a non-human primate model of AAV-mediated gene transfer to liver. Blood 110, 2334 2341.
15. Mochizuki S, Mizukami H, Kume A, Muramatsu S, Takeuchi K, Matsushita T, Okada T, Kobayashi E, Hoshika A Ozawa K (2004) Adeno-associated virus (AAV) vector-mediated liver- and muscle-directed transgene expression using various kinds of promoters and serotypes. Gene Ther Mol Biol 8, 9 18.
16. Nathwani AC, Gray JT, McIntosh J, Ng CYC, Zhou J, Spence Y, Cochrane M, Gray E, Tuddenham EGD Davidoff AM (2007) Safe and efficient transduction of the liver after peripheral vein infusion of self-complementary AAV vector results in stable therapeutic expression of human FIX in nonhuman primates. Blood 109, 1414 1421.
17. Ponder KP, Melniczek JR, Xu L, Weil MA, O'Malley TM, O'Donnell PA, Knox VW, Aguirre GD, Mazrier H, Ellinwood NM et al. (2002) Therapeutic neonatal hepatic gene therapy in mucopolysaccharidosis VII dogs. Proc Natl Acad Sci USA 99, 13102 11307.
18. Sferra T, Backstrom K, Wang C, Rennard R, Miller M Hu Y (2004) Widespread correction of lysosomal storage following intrahepatic injection of a recombinant adeno-associated virus in the adult MPS VII mouse. Mol Ther 10, 478 491.
19. Traas AM, Wang P, Ma X, Tittiger M, Schaller L, O'Donnell P, Sleeper MM, Vite C, Herati R, Aguirre GD et al. (2007) Correction of clinical manifestations of canine mucopolysaccharidosis I with neonatal retroviral vector gene therapy. Mol Ther 15, 1423 1431.
20. Fraldi A, Biffi A, Lombarda A, Visigalli I, Pepe S, Setiembre C, Nusco E, Auricchio A, Naldini L, Ballabio A et al. (2007) SUMF1 enhances sulfatase activities in vivo in five sulfatase deficiencies. Biochem J 403, 305 312.
21. Fraldi A, Hemsley H, Crawley A, Lombardi A, Lau A, Sutherland L, Auricchio A, Bollabio A Hopwood J (2007) Functional correction of CNS lesions in MPS-IIIA mouse model by intracerebral AAV-mediated delivery of sulfamidase and SUMF1 genes. Hum Mol Genet 16, 2693 2702.
22. Kurai T, Hisayasu S, Kitagawa R, Migita M, Suzuki H, Hirai Y Shimada T (2007) AAV1 mediated co-expression of formylglycine-generating enzyme and arylsulfatase A efficiently corrects sulfatide storage in a mouse model of metachromatic leukodystrophy. Mol Ther 15, 38 43.
23. Toietta G, Severini G, Traversari C, Tomatsu S, Sukegawa K, Fukuda S, Kondo N, Tortora P Bordignon C (2001) Various cells retrovirally transduced with N-acetylgalactosoamine-6-sulfate sulfatase correct Morquio skin fibroblasts in vitro. Hum Gene Ther 12, 2007 2016.
24. Brooks A, Harkins R, Wang P, Qian H, Liu P Rubanyi G (2004) Transcriptional silencing is associated with extensive methylation of the CMV promotor following adenoviral gene delivery to muscle. J Gene Med 6, 395 404.
25. Prosch S, Stein J, Staak K, Liebenthal C, Volk HD Kruger DH (1996) Inactivation of the very strong HCMV immediate early promoter by DNA CpG methylation in vitro. Biol Chem Hoppe Seyler 377, 195 201.
26. Foti S, Samulski R McCown T (2009) Delivering multiple gene products in the brain from a single adeno-associated virus vector. Gene Ther 16, 1314 1319.
27. Gutierrez M, Garcia-Vallejo F, Tomatsu S, Ceron F, Alméciga- Díaz C, Domínguez M Barrera L (2008) Construction of an adenoassociated virus-derived vector for the treatment of Morquio A disease. Biomedica 28, 448 459.
28. Ito T, Yamamoto S, Hayashi T, Kodera M, Mizukami H, Ozawa K Muramatsu S (2009) A convenient enzyme-linked immunosorbent assay for rapid screening of anti-adeno-associated virus neutralizing antibodies. Ann Clin Biochem 46, 508 510.
29. Han Z, Berendzen K, Zhong L, Surolia I, Chouthai N, Zhao W, Maina N, Srivastava A Stacpoole P (2008) A combined therapeutic approach for pyruvate dehydrogenase deficiency using self-complementary adeno-associated virus serotype-specific vectors and dichloroacetate. Mol Genet Metab 93, 381 387.
30. Teo E, Cross K, Bomsztyk E, Lyden D Spector JA (2009) Gene therapy in skin: choosing the optimal viral vector. Ann Plast Surg 62, 576 580.
31. Goodrich L, Choi V, Carbone B, McIlwraith C Samulski R (2009) Ex vivo serotype-specific transduction of equine joint tissue by self-complementary adeno-associated viral vectors. Hum Gene Ther 20, 1697 1702.
32. Alexander I, Cunningham S, Logan G Cristodoulou J (2008) Potential of AAV vectors in the treatment of metabolic disease. Gene Ther 15, 831 839.
33. Carter B (2005) Adeno-associated virus vectors in clinical trials. Hum Gene Ther 16, 541 550.
34. Wu Z, Asokan A Samulski R (2006) Adeno-associated virus serotypes: vector toolkit for human gene therapy. Mol Ther 14, 316 327.
35. Hacein-Bey-Abina S, Garrigue A, Wang GP, Soulier J, Lim A, Morillon E, Clappier E, Caccavelli L, Delabesse E, Beldjord K et al. (2008) Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1. J Clin Invest 118, 3132 3142.
36. Edelstein ML, Abedi MR Wixon J (2007) Gene therapy clinical trials worldwide to 2007 - an update. J Gene Med 9, 833 842.
37. Zaiss AK Muruve DA (2005) Immune responses to adeno-associated virus vectors. Curr Gene Ther 5, 323 331.
38. Donsante A, Miller DG, Li Y, Vogler C, Brunt EM, Russell DW Sands MS (2007) AAV vector integration sites in mouse hepatocellular carcinoma. Science 317, 477.
39. Papadakis E, Nicklin S, Baker A White S (2004) Promoters and control elements: designing expression cassettes for gene therapy. Curr Gene Ther 4, 89 113.
40. Huang M Gorman C (1990) Intervening sequences increase efficiency of RNA 3′ procesing and accumulation of cytoplasmic RNA. Nucleic Acids Res 18, 937 947.
41. Valencia P, Dias AP Reed R (2008) Splicing promotes rapid and efficient mRNA export in mammalian cells. Proc Natl Acad Sci USA 105, 3386 3391.
42. Zhao C Hamilton T (2007) Introns regulate the rate of unstable mRNA decay. J Biol Chem 282, 20230 20237.
43. Azzoni AR, Ribeiro SC, Monteiro GA Prazeres DM (2007) The impact of polyadenylation signals on plasmid nuclease-resistance and transgene expression. J Gene Med 9, 392 402.
44. Xu ZL, Mizuguchi H, Ishii-Watabe A, Uchida E, Mayumi T Hayakawa T (2002) Strength evaluation of transcriptional regulatory elements for transgene expression by adenovirus vector. J Control Release 81, 155 163.
45. Yew NS, Wysokenski DM, Wang KX, Ziegler RJ, Marshall J, McNeilly D, Cherry M, Osburn W Cheng SH (1997) Optimization of plasmid vectors for high-level expression in lung epithelial cells. Hum Gene Ther 8, 575 584.
46. Stoneley M Willis AE (2004) Cellular internal ribosome entry segments: structures, trans-acting factors and regulation of gene expression. Oncogene 23, 3200 3207.
47. Hennecke M, Kwissa M, Metzger K, Oumard A, Kroger A, Schirmbeck R, Reimann J Hauser H (2001) Composition and arrangement of genes define the strength of IRES-driven translation in bicistronic mRNAs. Nucleic Acids Res 29, 3327 3334.
48. Vargas J Jr., Gusella GL, Najfeld V, Klotman ME Cara A (2004) Novel integrase-defective lentiviral episomal vectors for gene transfer. Hum Gene Ther 15, 361 372.
49. Kim I, Józkowicz A Piedra P (2001) Lifetime correction of genetic deficiency in mice with a single injection of helper-dependent adenoviral vector. Proc Natl Acad Sci USA 98, 13282 13287.
50. Watson G, Sayles J, Chen C, Elliger S, Elliger C, Raju N, Kurtzman G Podsakoff G (1998) Treatment of lysosomal storage disease in MPS VII mice using a recombinant adeno-associated virus. Gene Ther 5, 1642 1649.
51. Toniatti C, Bujard H, Cortese R Ciliberto C (2004) Gene therapy progress and prospects: transcription regulatory systems. Gene Ther 11, 649 657.
52. Ghazizadeh S, Carroll JM Taichman LB (1997) Repression of retrovirus-mediated transgene expression by interferons: implications for gene therapy. J Virol 71, 9163 9169.
53. Qin L, Ding Y, Pahud DR, Chang E, Imperiale MJ Bromberg JS (1997) Promoter attenuation in gene therapy: interferon-gamma and tumor necrosis factor-alpha inhibit transgene expression. Hum Gene Ther 8, 2019 2029.
54. Alméciga-Díaz C, Rueda-Paramo M, Espejo A, Echeverri O, Montano A, Tomatsu S Barrera L (2009) Effect of elongation factor 1 promoter and SUMF1 over in-vitro expression of N-acetylgalactosamine-6-sulfate sulfatase. Mol Biol Rep 36, 1863 1870.
55. Chan K, Wu S, Nissom P, Oh S Choo A (2008) Generation of high-level stable transgene expressing human embryonic stem cell lines using Chinese hamster elongation factor-1 alpha promoter system. Stem Cells Dev 17, 825 836.
56. Gerolami R, Uch R, Jordier F, Chapel S, Bagnis C, Bréchot C Mannoni P (2000) Gene transfer to hepatocellular carcinoma: transduction efficacy and transgene expression kinetics by using retroviral and lentiviral vectors. Cancer Gene Ther 7, 1286 1292.
57. Jenke A, Scinteie M, Stehle I Lipps H (2004) Expression of a transgene encoded on a non-viral episomal vector is not subject to epigenetic silencing by cytosine methylation. Mol Biol Rep 31, 85 90.
58. Krishnan M, Park J, Cao F, Wang D, Paulmurugan R, Tseng J, Gonzalgo M, Gambhir S Wu J (2006) Effects of epigenetic modulation on reporter gene expression: implications for stem cell imaging. FASEB J 20, 106 108.
59. Zhao G, Karageorgos L, Hutchinson R, Hoopwood J Hemsley K (2010) Genetic manipulation of murine embryonic stem cells with enhanced green fluorescence protein and sulfatase-modifying factor I genes. Cytotherapy 12, 400 407.
60. Stilwell JL Samulski RJ (2004) Role of viral vectors and virion shells in cellular gene expression. Mol Ther 9, 337 346.
61. McCaffrey AP, Fawcett P, Nakai H, McCaffrey RL, Ehrhardt A, Pham TT, Pandey K, Xu H, Feuss S, Storm TA et al. (2008) The host response to adenovirus, helper-dependent adenovirus, and adeno-associated virus in mouse liver. Mol Ther 16, 931 941.
62. Chung S, Ma X, Liu Y, Lee D, Tittiger M Ponder KP (2007) Effect of neonatal administration of a retroviral vector expressing a-L-iduronidase upon lysosomal storage in brain and other organs in mucopolysaccharidosis I mice. Mol Genet Metab 90, 181 192.
63. Wang B, O'Malley TM, Xu L, Vite C, Wang P, O'Donnell PA, Ellinwood NM, Haskins ME Ponder KP (2006) Expression in blood cells may contribute to biochemical and pathological improvements after neonatal intravenous gene therapy for mucopolysaccharidosis VII in dogs. Mol Genet Metab 87, 8 21.
64. Mount J, Herzog R Tillson M (2002) Sustained phenotypic correction of hemophilia B dogs with a factor IX null mutation by liver-direct gene therapy. Blood 99, 2670 2675.
65. Rodríguez-Antona C, Donato M, Boobis A, Edwards R, Watts P, Castell J Gómez-Lechón M (2002) Cytochrome P450 expression in human hepatocytes and hepatoma cell lines: molecular mechanisms that determine lower expression in cultured cells. Xenobiotica 32, 505 520.
66. Alon U (2007) Network motifs: theory and experimental approaches. Nat Rev Genet 8, 450 461.
67. Sandelin A, Carninci P, Lenhard B, Ponjavic J, Hayashizaki Y Hume D (2007) Mammalian RNA polymerase II core promoters: insights from genome-wide studies. Nat Rev 8, 424 436.
68. Gill D, Smyth S, Goddard C, Pringle I, Higging C, Coledge W Hyde S (2001) Increased persistence of lung gene expression using plasmids containing the ubiquitin C or elongation factor 1a promoter. Gene Ther 8, 1539 1546.
69. Liu Y, Okada T, Nomoto T, Ke X, Kume A, Ozawa K Xiao S (2007) Promoter effects of adeno-associated viral vector for transgene expression in the cochlea in vivo. Exp Mol Med 39, 170 175.
70. Song S, Emburry J, Laipis P, Berns K, Crawford J Flotte T (2001) Stable therapeutic serum levels of human alpha-1 antitrypsin (AAT) after portal vein injection of recombinant adeno-associated virus (AAV) vectors. Gene Ther 8, 1299 1306.
71. Teschendorf C, Warrington K, Siemann D Muzyczka N (2002) Comparison of the EF-1 alpha and the CMV promoter for engineering stable tumor cell lines using recombinant adeno-associated virus. Anticancer Res 22, 3325 3330.
72. Xu L, Daly T, Gao C, Flotte T, Song S, Byrne B, Sands M Ponder K (2001) CMV - actin promoter directs higher expression from an adeno-associated viral vector in the liver than the cytomegalovirus or elongation factor 1a promoter and results in therapeutic levels of human factor X in mice. Hum Gene Ther 12, 563 573.
73. Cosma M, Pepe P, Annunziata I, Newbold R, Grompe M, Parenti G Ballabio A (2003) The multiple sulfatase deficiency gene encodes an essential and limiting factor for the activity of sulfatases. Cell 113, 445 456.
74. Takakusaki T, Hisayasu S, Hirai Y Shimada T (2005) Coexpression of formylglycine-generating enzyme is essential for synthesis and secretion of functional arylsulfatase A in a mouse model of metachromatic leukodystrophy. Hum Gene Ther 16, 929 936.
75. Ponder K Haskins M (2007) Gene therapy for mucopolysaccharidosis. Expert Opin Biol Ther 7, 1333 1345.
76. Sands M Davidson B (2006) Gene therapy for lysosomal storage diseases. Mol Ther 13, 839 849.
77. Liu Y, Xu L, Henning A, Kovacs A, Fu A, Chung S, Lee D, Wang B, Herati R, Ogilvem J et al. (2005) Liver-directed neonatal gene therapy prevents cardiac, bone, ear, and eye disease in mucopolysaccharidosis I mice. Mol Ther 11, 35 47.
78. Cardone M, Polito VA, Pepe S, Mann L, D'Azzo A, Auricchio A, Ballabio A Cosma MP (2006) Correction of Hunter syndrome in the MPSII mouse model by AAV28-mediated gene delivery. Hum Mol Genet 15, 1225 1236.
79. Mango RL, Xu L, Sands MS, Vogler C, Seiler G, Schwarz T, Haskins ME Ponder KP (2004) Neonatal retroviral vector-mediated hepatic gene therapy reduces bone, joint, and cartilage disease in mucopolysaccharidosis VII mice and dogs. Mol Genet Metab 82, 4 19.
80. Zincarelli C, Soltys S, Rengo G Rabinowitz JE (2008) Analysis of AAV serotypes 1-9 mediated gene expression and tropism in mice after systemic injection. Mol Ther 16, 1073 1080.
81. Tomatsu S, Montano AM, Dung V, Ohashi A, Oikawa H, Oguma T, Orii T, Barrera L Sly W (2010) Enhacement of drug delivery: enzyme-replacement therapy for murine Morquio A syndrome. Mol Ther 18, 1094 1102.
82. Zolotukhin S, Byrne B, Mason E, Zolotukhin I, Potter M, Chesnut K, Summerford C, Samulski R Muzyczka N (1999) Recombinant adeno-associated virus purification using novel methods improves infectious titer and yield. Gene Ther 6, 973 985.
83. Sommer M Jr., Smith PH, Parthasarathy S, Isaacs J, Vijay S, Kieran J, Powell SK, McClelland A Wright JF (2003) Quantification of adeno-associated virus particles and empty capsids by optical density measurement. Mol Ther 7, 122 128.
84. Tomatsu S, Orii K, Vogler C, Nakayama J, Levy B, Grubb J, Gutierrez M, Shim S, Yamaguchi S, Nishioka T et al. (2003) Mouse model of N-acetylgalactosamine-6-sulfate sulfatase deficiency (Galns - ) produced by targeted disruption of the gene defective in Morquio A disease. Hum Mol Genet 12, 3349 3358.
85. van Diggelen O, Zhao H, Kleijer W, Janse H, Poorthuis B, Pelt Jv, Kamerling J Galjaard H (1990) A fluorometric enzyme assay for the diagnosis of Morquio disease type A (MPS IVA). Clin Chem Acta 187, 131 140.